A rapidly aging population, rising rates of chronic illnesses, growing healthcare needs, and advancements in technology are all contributing to the long-term growth of the pharmaceutical sector.
Despite the favorable conditions, not all pharma stocks are expected to deliver. Hence, it could be wise to avoid Madrigal Pharmaceuticals, Inc. (MDGL). Meanwhile, investors could wait for a better entry point in Pfizer Inc. (PFE). On the other hand, one could consider buying Astellas Pharma Inc. (ALPMY) and Novo Nordisk A/S (NVO), given their strong fundamentals and growth prospects.
